Fulcrum Therapeutics (FULC) Receivables - Other (2020 - 2025)

Fulcrum Therapeutics (FULC) has 6 years of Receivables - Other data on file, last reported at $979000.0 in Q1 2025.

• Receivables - Other for Q1 2025 came in at $979000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2025 was $979000.0 (changed N/A YoY), and the FY2024 annual result was $2.1 million, up 290.32% from the prior year.
• Receivables - Other eased to $979000.0 in Q1 2025 per FULC's latest filing, from $2.1 million in the prior quarter.
• Over five years, Receivables - Other peaked at $3.7 million in Q3 2024 and troughed at $100000.0 in Q3 2022.
• A 5-year average of $1.1 million and a median of $743000.0 in 2022 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2022 and 2024: Receivables - Other plunged 79.86% in 2022, then jumped 530.34% in 2024.
• A 5-year view of Receivables - Other shows it stood at $1.1 million in 2021, then plunged by 79.86% to $229000.0 in 2022, then soared by 134.5% to $537000.0 in 2023, then jumped by 290.32% to $2.1 million in 2024, then sank by 53.29% to $979000.0 in 2025.
• Business Quant data shows FULC's Receivables - Other at $979000.0 in Q1 2025, $2.1 million in Q4 2024, and $3.7 million in Q3 2024.